Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators

Area of Science:

• Neurology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Recombinant tissue plasminogen activator (alteplase) received conditional licensure for acute ischemic stroke (AIS) in Canada in 1999.
• The Canadian Activase for Stroke Effectiveness Study (CASES) was mandated to monitor alteplase use in AIS patients.
• CASES involves collaboration among multiple stakeholders in stroke care.

Purpose of the Study:

• To ensure the safety of alteplase for AIS treatment within the Canadian healthcare system.
• To evaluate the effectiveness of alteplase in treating AIS patients.
• To identify patient subgroups most likely to benefit from alteplase therapy.

Main Methods:

• CASES is a prospective registry collecting data on patients treated with alteplase for AIS.
• Data is gathered from both community and tertiary healthcare centers.
• The registry tracks patient outcomes and treatment administration.

Main Results:

• A total of 944 patients have been enrolled across 60 centers (25 community, 35 tertiary).
• Preliminary results demonstrate that thrombolytic stroke treatment is both safe and effective.
• The study provides real-world data on alteplase utilization in AIS.

Conclusions:

• The CASES study provides a framework for multi-stakeholder collaboration in stroke care.
• The study's development and methods are outlined, showcasing a collaborative approach.
• CASES contributes to advancing the care of patients with acute stroke through ongoing monitoring and evaluation.